Effects of acute and sub-acute treatment with metformin on cardiovascular responses to a glucose challenge in type 2 diabetes

Royal Adelaide Hospital0 个研究点目标入组 18 人开始时间: 2019年7月30日最近更新: 2019年12月10日

试验速览

暂无简介。

•Type 2 diabetes (World Health Organisation (WHO) criteria), managed by diet only
•Body mass index (BMI) 25 - 35 kg/m2
•Males and females, aged 40-80 years
•Glycated haemoglobin (HbA1c) 6- 8.5%
•Haemoglobin above the lower limit of the normal range (ie. >135g/L for men and 115g/L for women), and ferritin above the lower limit of normal (ie. >30ng/mL for men and >20mg/mL for women)
•Patients on stable doses of antihypertensives will be included.

•Use of any medication that may influence gastrointestinal motor function, body weight or appetite (opiates, anticholinergics, levodopa, clonidine, nitrates, tricyclic antidepressants, selective serotonin re-uptake inhibitors, phosphodiesterase type 5 inhibitors, sumatriptan, metoclopramide, domperidone, cisapride, prucalopride, or erythromycin)
•Evidence of drug abuse, consumption of more than 20 g alcohol or 10 cigarettes on a daily basis
•History of gastrointestinal disease, including significant upper or lower gastrointestinal symptoms, pancreatitis, or previous gastrointestinal surgery (other than uncomplicated appendicectomy or cholecystectomy)
•Other significant illness, including epilepsy, cardiovascular or respiratory disease
•Impaired renal or liver function (as assessed by calculated creatinine clearance < 60 mL/min or abnormal liver function tests (> 2 times upper limit of normal range))
•Donation of blood within the previous 3 months
•Participation in any other research studies within the previous 3 months
•Inability to give informed consent
•Female participants who are not on long acting contraception
•Previously unable to tolerate metformin or treatment with metformin within the past week.

发起方